What's in National Center for Research Resources (NCRR)'s pipeline?

National Center for Research Resources (NCRR) has 11 drugs in our index: 5 marketed, 0 filed, 4 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with National Center for Research Resources (NCRR)'s portfolio?

Top competitors by shared drug class: Beijing Children's Hospital, Active Biotech AB, Air Force Military Medical University, China, Al-Azhar University, Astellas Pharma Inc.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/national-center-for-research-resources-ncrr.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

National Center for Research Resources (NCRR) — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

National Center for Research Resources (NCRR) pipeline: 5 marketed, 0 filed, 4 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 4 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Hawthorn	Hawthorn	marketed			Other
von Willebrand factor	von Willebrand factor	marketed	Coagulation factor replacement	Von Willebrand factor receptor (GPIb-IX-V complex on platelets); Factor VIII binding site	Hematology
polystyrene sulfonate	polystyrene sulfonate	marketed	Ion-exchange resin		Nephrology / Electrolyte Management
ribose	ribose	marketed			Other
megestrol	megestrol	marketed		Cytochrome P450 2C9, Multidrug resistance protein 1, Glucocorticoid receptor	Oncology
copolymer 1	copolymer 1	phase 3	Immunomodulator	Myelin basic protein	Neurology
,4-diaminopyridine	,4-diaminopyridine	phase 3	Potassium channel blocker	Voltage-gated potassium channels (presynaptic)	Neurology
soy protein isolate	soy protein isolate	phase 3
tumor-pulsed dendritic cells	tumor-pulsed dendritic cells	phase 3			Oncology

Therapeutic area mix

Neurology · 2
Oncology · 2
Other · 2
Hematology · 1
Neuroscience · 1
Metabolic · 1
Nephrology / Electrolyte Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Beijing Children's Hospital · 2 shared drug classes
Active Biotech AB · 1 shared drug class
Air Force Military Medical University, China · 1 shared drug class
Al-Azhar University · 1 shared drug class
Astellas Pharma Inc · 1 shared drug class
Bayer · 1 shared drug class
Actavis Mid-Atlantic LLC · 1 shared drug class
ALK-Abelló A/S · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for National Center for Research Resources (NCRR):

Cite this brief

Drug Landscape (2026). National Center for Research Resources (NCRR) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/national-center-for-research-resources-ncrr. Accessed 2026-05-18.